• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00
    Get the next $NATR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nature's Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock

      LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the "Selling Stockholder"). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions. The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stoc

      6/26/25 6:30:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Products, Inc. Announces Launch of Secondary Public Offering of Common Stock

      LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the "Selling Stockholder"). The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions and transfer taxes at

      6/25/25 4:01:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Announces Leadership Transition Plan

      Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

      6/2/25 9:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DA Davidson resumed coverage on Nature's Sunshine with a new price target

      DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

      5/7/25 8:37:48 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

      Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

      9/13/24 7:38:59 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

      DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

      3/9/22 9:23:08 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    SEC Filings

    See more
    • SEC Form 8-K filed by Nature's Sunshine Products Inc.

      8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      6/27/25 8:31:04 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nature's Sunshine Products Inc.

      424B5 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      6/27/25 7:23:14 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nature's Sunshine Products Inc.

      424B5 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      6/25/25 4:01:22 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. sold $32,713,796 worth of shares (2,854,607 units at $11.46) (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      6/27/25 4:27:23 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Fosun Pharma Usa Inc. claimed ownership of 2,854,607 shares (SEC Form 3)

      3 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      6/9/25 4:32:08 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fasching Steven J. was granted 8,000 shares, increasing direct ownership by 279% to 10,869 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/7/25 1:25:23 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Nature's Sunshine Announces Leadership Transition Plan

      Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

      6/2/25 9:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Katie A. May to Board of Directors

      LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine serving as independent directors. "Katie brings significant experience scaling and leading high-growth B2C, ecommerce and logistics companies," said Richard D. Moss, Chairman of the Board of Nature's Sunshine. "Her deep understanding of the full ecommerce lifecycle will strengthen and enhance our digital capabilities and drive s

      2/5/25 4:05:00 PM ET
      $NATR
      $PBI
      $STMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Office Equipment/Supplies/Services
      Miscellaneous

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/12/24 10:37:49 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      1/31/24 11:56:05 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/13/23 2:42:04 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Financials

    Live finance-specific insights

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Sets First Quarter 2025 Conference Call for Tuesday, May 6, 2025, at 5:00 p.m. ET

      LEHI, Utah, April 22, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, May 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, May 6, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-free di

      4/22/25 4:04:59 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Reports Fourth Quarter and Full Year 2024 Financial Results

      LEHI, Utah, March 11, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were up 8.5% to $118.2 million compared to $108.9 million (up 10.0% in constant currency).GAAP net loss attributable to common shareholders of $0.3 million, or $(0.02) per diluted share, compared to net income of $9.0 million, or $0.46 per diluted share.Adjusted EBITDA up 6% to $10.3 million com

      3/11/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care